CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)

Trial Details

NCT ID

NCT05410717

Phase

PHASE1

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

patients with advanced ovarian cancer or other cancers with expression of claudin6.
Life expectancy \>12 weeks
Adequate heart,lung,liver,kidney function
Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR determined by flow-…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →